Healthpoint, Ltd, Fort Worth, Texas, announced it will begin marketing its Collagenase SANTYL Ointment to healthcare professionals in Canada. The product is a selective enzymatic agent indicated for debriding chronic dermal ulcers (eg, pressure, vascular, and diabetic ulcers) and severely burned areas. Reportedly, it will be the only enzymatic debrider available in the Canadian market.
In additional news, Healthpoint, Ltd, has acquired 2 cell-based technologies from Intercytex Limited, Manchester, United Kingdom, along with the corresponding intellectual property (including patents), validated fibroblast and keratinocyte cell banks, and related production and testing equipment. Terms of the deal were not disclosed by Healthpoint. The therapeutic candidates acquired include CYZACT-human dermal fibroblasts delivered via a fibrin sheet and produced using a streamlined manufacturing process as compared with similar products-and ICX-SKN-a combination of fibroblasts and fibrin matrix that are remodeled to produce a collagen matrix that allows the engineered tissue to remain intact in a hostile wound environment.
KCI, San Antonio, Texas, joined the many companies and organizations contributing to the Haiti relief effort, following that nation's devastating earthquake. Its initial contribution of more than $2 million of advanced wound care products included V.A.C. Freedom Therapy units to help provide negative pressure wound therapy to individuals with compound fractures and large tissue deficits at high risk of infection.
ConvaTec, Skillman, New Jersey, was also among the many companies involved in donating medical supplies to relief efforts in Haiti, making an initial donation of more than $400,000. Working through the ConvaTec manufacturing facility in Haina, Dominican Republic, which was unaffected by the quake, the donation consisted of advanced wound dressings and skin care products, which were stocked at the facility.
In other news, ConvaTec has also announced today its platinum sponsorship for the 4th Congress of the World Union of WoundHealing Societies, which will take place in Yokohama, Japan, from September 2 to 7, 2012.
Charles Stiefel, the former chief executive officer of Stiefel Laboratories dermatology firm, has been appointed to the board of directors for Electro-Optical Sciences (EOS), Irvington, New York. EOS is a medical technology company focused on developing MelaFind, a noninvasive and objective computer vision system intended to aid in the early detection of melanoma. Mr Stiefel has more than 25 years of experience in the dermatology industry.